A single-center, double-blind, randomized, cross-over, placebo-controlled, single-dose study to investigate glycemic parameters of efficacy during 24 hours, safety/ tolerability and pharmacokinetics of two dose levels of RO4998452 in patients with type 2 diabetes mellitus
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2016
At a glance
- Drugs Tofogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Roche
- 15 Sep 2010 Status changed from recruiting to completed as reported by Roche.
- 08 Jan 2010 Planned end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 08 Jan 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health)(NCT01044017).